Investment highlights2019-03-21T23:36:47+00:00

Investment Highlights

prescient therapeutics investment highlights
  • 2 targeted therapies with impeccable scientific pedigree

  • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials

  • One of deepest clinical pipelines on the ASX
    – Targeting important areas of unmet clinical need

  • Funded through to value-accretive catalysts, with a fantastic share register

  • Phase 1b/2 AML trial is being led by renowned leukemia expert, Dr Jeff Lancet
    – Dr Lancet was also the Principal Investigator on Celator Pharmaceuticals’ ground-breaking VYXEOS trial in AML

  • Great scientific and clinical team with a proven record of success

  • Multiple catalysts this year


The broker reports included on this page of the website have not been commissioned or endorsed by Prescient Therapeutics Limited (Prescient) or its officers and are provided for information purposes only.  The information contained in these report is not produced by Prescient and is not intended to be investment or financial product advice given by Prescient.  Prescient recommends recipients of the reports make their own assessment of Prescient before making any investment decision. Any inquiries with respect to the reports should be directed to the relevant issuer of the report.